STOCK TITAN

HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

HCW Biologics (HCWB) reported a narrower third-quarter net loss while advancing its HCW9302 clinical trial and securing debt financing. Quarterly revenue rose to $55,463 from $15,606, and net loss narrowed to $3,222,829 from $4,554,336. Nine-month revenue reached $6,734,032, versus $27,222, following completion of the Trimmune license agreement and additional services.

HCW9302 enrollment continued in the third dose cohort, with no dose-limiting toxicities in patients treated to date. The company expects a Phase 1 readout and recommended Phase 2 dose in the first quarter of 2027, and plans an HCW11-018b investigational new drug application in the first half of 2027. November debt financing provided $3.0 million less transaction costs, with another $7.0 million conditional. Cash was $955,458 at September 30; substantial doubt remains about the company's ability to continue as a going concern without additional funding.

Loading...
Loading translation...

Positive

  • Third-quarter revenue increased to $55,463 from $15,606 a year earlier.
  • Nine-month revenue increased to $6,734,032 from $27,222 a year earlier.
  • Third-quarter net loss narrowed to $3,222,829 from $4,554,336; nine-month loss narrowed to $4,969,581 from $8,678,941.
  • Loss per share narrowed to $2.83 quarterly and $13.35 year-to-date, versus $12.09 and $68.02, respectively.
  • Third-quarter research and development expenses fell 12%; nine-month expenses fell 10% year over year.
  • Third-quarter general and administrative expenses fell 28%; nine-month expenses fell 18% year over year.
  • Trimmune's exclusive worldwide license for HCW11-006 in vivo rights closed, with additional post-transfer services performed.
  • AlloTera license termination restored exclusive rights to the previously licensed molecules.
  • Equity financing raised $8.6 million during the nine months ended September 30, 2026.
  • November 4 debt financing delivered $3.0 million, less transaction costs, with up to $10.0 million available overall.
  • The company believes financing supports HCW9302 Phase 1 completion and dose selection in the first quarter of 2027.
  • HCW9302 added a third clinical site and continued enrollment and treatment at eight micrograms/kg body weight.
  • HCW9302 was well-tolerated, with no dose-limiting toxicities in patients treated to date.
  • The company plans to present full HCW9302 Phase 1 results in March 2027 at the Treg-Directed Therapies Summit.
  • HCW11-018b received FDA guidance on preparation of an investigational new drug application, planned for first-half 2027.
  • HCW11-018b manufacturing under current good manufacturing practices has begun to support potential clinical trials.
  • Nine-month interest expense declined to $351,612 from $632,923 a year earlier.
  • Nine-month gain on extinguishment of a liability totaled $483,383.
  • Total liabilities declined to $18,303,756 at September 30, 2026, from $21,755,244 at December 31, 2025.
  • Stockholders' equity increased to $6,823,240 from $2,764,769 at December 31, 2025.
  • Investments increased to $4,854,028 from $1,326,329 at December 31, 2025.
  • Nasdaq confirmed bid-price and other continued-listing compliance through September 22, 2026, as required by its panel.

Negative

  • The company reports substantial doubt about continuing as a going concern without additional funding or support.
  • Cash declined to $955,458 at September 30, 2026, from $1,952,464 at December 31, 2025.
  • Current liabilities of $17,611,225 exceeded current assets of $1,280,658 at September 30, 2026.
  • November financing adds debt; access to the additional $7.0 million remains subject to conditions.
  • Issued common shares increased to 2,236,324 from 546,635 at December 31, 2025, diluting existing holders.
  • Quarterly loss attributable to common stockholders widened to $5,941,666 from $4,554,336; nine-month loss widened to $19,331,532 from $18,832,740.
  • Equity dividends to an investor totaled $2,718,837 quarterly and $14,361,951 year-to-date, versus zero and $10,153,799.
  • Return of equipment produced a $494,683 loss in the third quarter.
  • Nine-month warrant-liability fair-value change produced a $1,775,992 loss.
  • Nine-month legal expenses were $14,583, versus net recoveries of $1,590,945 a year earlier.
  • Settlement compliance is expected to require continuing expenses, primarily for patent requirements.
  • Nine-month indirect tax expense was $198,146, versus none a year earlier.
  • Nine-month income tax expense was $330,186, versus none a year earlier.
  • Third-quarter interest expense increased to $141,797 from $127,070 a year earlier.
  • Other income declined to $3,554 quarterly and $19,992 year-to-date, versus $13,290 and $54,412.

News Explained

The company reported $8.6 million of equity financing in the first nine months of 2026; issued shares rose from 546,635 at December 31, 2025, to 2,236,324 at September 30, 2026, reducing existing holders’ percentage ownership absent offsetting changes.

Key Figures

Three-month revenue: $55,463 vs. $15,606 Nine-month revenue: $6,734,032 vs. $27,222 Three-month net loss: $3,222,829 vs. $4,554,336 +4 more
Three-month revenue
$55,463 vs. $15,606
Three months ended September 30, 2026 vs. 2025
Nine-month revenue
$6,734,032 vs. $27,222
Nine months ended September 30, 2026 vs. 2025
Three-month net loss
$3,222,829 vs. $4,554,336
Three months ended September 30, 2026 vs. 2025
Nine-month net loss
$4,969,581 vs. $8,678,941
Nine months ended September 30, 2026 vs. 2025
Debt financing
Up to $10.0 million; $3.0 million received at closing and an additional $7.0 million subject to conditions
Financing closed November 4, 2026
Phase 1 readout and dose determination
Expected in the first quarter of 2027
HCW9302 study in alopecia areata
Going-concern period
At least 12 months
Substantial doubt exists without additional funding or financial support

Previous Earnings,clinical trial Reports

1 past event · Latest: Aug 14
Same Type 1 event
  1. Aug 14

    2Q earnings

    24h Move
    -8.4%

    HCW9302 cohort data showed ≥25% SALT reductions in all three patients, without dose-limiting toxicities

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dose-limiting toxicities, recommended phase 2 dose, ind application, cgmp
4 terms
dose-limiting toxicities medical
"has been well-tolerated and has had no dose-limiting toxicities"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
ind application regulatory
"prepare its IND application to support a first-in-human clinical study"
An Investigational New Drug (IND) application is a formal request to regulators to allow a drug or biologic to be tested in people. It bundles lab and animal safety data, manufacturing details, and a plan for human trials—think of it like a building permit that lets developers move from design to construction. For investors, IND approval is a key milestone that permits clinical testing, reduces regulatory uncertainty, and can materially affect a company’s timeline, risk profile, and valuation.
cgmp technical
"initiated cGMP manufacturing of HCW11-018b"
cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MIRAMAR, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and nine months ended September 30, 2026.

The Company featured two of its preclinical, non-Fc TRBC molecules at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (“SITC2026”) which took place from November 4 – 8, 2026 in Phoenix, Arizona. In addition, the Company showcased the uniqueness of its TRBC platform to create novel multivalent non-Fc fusion molecules for solid tumor and senescence-associated diseases therapies.

The submission for the Company’s second-generation, tetravalent immune checkpoint inhibitor, HCW11-040, was recognized by SITC2026 as one of the top 150 abstracts out of over 1,200 abstracts submitted for its scientific rigor, novelty, clarity and potential impact on cancer immunotherapy. In the Poster presentation of its T Cell Engager Program, the Company shared the newly discovered, distinctive features of its lead product candidate in this program, HCW11-018b, including capabilities to induce/promote tertiary lymphoid structure formation inside tumors, convert immunological “cold” tumors into “hot” tumors, and enhance T-cell activation and tumor infiltration while mitigating immunosuppression, using subcutaneous (“s.c.”) administration.

In the three months ended September 30, 2026, the Company activated an additional clinical site to participate in the HCW9302 Phase 1 clinical study in alopecia areata and continued patient enrollment and treatment in the third dose cohort (i.e., eight (8) micrograms/kg body weight). In patients treated to date, the s.c. administration of HCW9302 has been well-tolerated and has had no dose-limiting toxicities. With continued patient enrollment, the Phase 1 readout and determination of the Recommended Phase 2 Dose are expected in the first quarter of 2027. The Company intends to present the full results of the Phase 1 clinical trial in an invited oral presentation at the 9th Treg-Directed Therapies Summit in March 2027 in Boston, Massachusetts.

Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, “Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”

Business and Clinical Development Highlights

In the nine months ended September 30, 2026, the Company raised $8.6 million of equity financing, which allowed it to continue to support a Phase 1 clinical study to evaluate HCW9302 in an autoimmune disease and advance preclinical programs, especially the Company’s T-Cell Engager Program. On November 4, 2026, the Company secured up to $10.0 million in cash through debt financing, and received $3.0 million, less transaction costs, at closing and access to an additional $7.0 million, subject to certain conditions. With this financing, the Company believes it has funding in place to reach the milestone of completion of the Phase 1 clinical trial for HCW9302 and determining the Recommended Phase 2 Dose level, which are expected in the first quarter of 2027.

As a result of discussions at a recent Type B meeting with the U.S. Food and Drug Administration (“FDA”), the FDA provided the Company with clear guidance for the next steps to prepare its IND application to support a first-in-human clinical study to evaluate HCW11-018b in solid tumors, which the Company intends to file in the first half of 2027. In support of potential upcoming clinical trials, the Company has initiated cGMP manufacturing of HCW11-018b. HCW Biologics has created a high-expression production cell line and a streamlined GMP manufacturing process, utilizing a relatively simple manufacturing process that is similar to the process used to make therapeutic monoclonal antibodies.

Third Quarter 2026 Financial Results

Revenues: Revenues for the three months ended September 30, 2025 and 2026 were $15,606 and $55,463, respectively. Revenues in the nine months ended September 30, 2025 and 2026 were $27,222 and $6.7 million, respectively. In the three and nine months ended September 30, 2025, at the request of the licensee, the Company agreed to suspend the license with AlloTera Therapeutics, Inc. (“AlloTera Therapeutics”), thus the Company recognized revenues related only to minor ancillary services such as storage. In the nine months ended September 30, 2026, the Company elected to terminate the license with AlloTera Therapeutics and recaptured the exclusive rights to the licensed molecules. In the nine months ended September 30, 2026, the Company completed the closing of the exclusive, worldwide licensing agreement with Beijing Trimmune Biotech Co., Ltd. (“Trimmune”) for the in vivo rights for HCW11-006 (“Trimmune License”) and performed additional post-transfer services under the agreement.

Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2025 and 2026 were $1.4 million and $1.2 million, respectively, a decrease of $161,670, or 12%. The decrease was primarily due to decreases in salaries, benefits and related taxes and preclinical expenses. R&D expenses for the nine months ended September 30, 2025 and 2026 were $4.1 million and $3.7 million, respectively, a decrease of $405,905, or 10%. The decrease was primarily due to a decline in manufacturing and materials expenses, partially offset by increases in taxes and salaries, benefits and related expenses.

General and administrative (G&A) expenses: G&A expenses for the three months ended September 30, 2025 and 2026 were $1.8 million and $1.4 million, respectively, a decrease of $518,608, or 28%. The decrease was primarily attributable to decreases in stock-based compensation expense and a decline in fees paid for professional services, such as corporate legal advice, legal advice for prosecution of patents, auditing and tax services, and other professional services. G&A expenses for the nine months ended September 30, 2025 and 2026, were $6.2 million and $5.1 million, respectively, a decrease of $1.1 million, or 18%. The decrease was primarily attributable to decreases in stock-based compensation expense, professional services and insurance premiums.

Legal expenses (recoveries), net: Legal expenses and recoveries, net represent the legal fees that the Company incurred for an Arbitration, net of insurance recoveries. In the nine months ended September 30, 2025, the Company received a $2.0 million insurance recovery, partially offset by $409,055 of legal expenses. In the nine months ended September 30, 2026, there were expenses of $14,483. The Company anticipates it will continue to incur some expenses for the costs of remaining in compliance with the terms of the Settlement and Release Agreement from the Arbitration, primarily due to requirements for patents which are necessary to protect the Company’s exclusive, worldwide intellectual property rights held in perpetuity.

Nonoperating changes impacting net income (loss): In the three months ended September 30, 2025, the was a decrease in fair value of $966,284 related to the change in the fair value of the Company’s shares in AlloTera Therapeutics and the related contingent liability, and a loss of $182,146 on the sale of put shares through the Company’s Standby Equity Purchase Agreement. In the three months ended September 30, 2026, there was a $494,683 loss on the return of equipment.

In the nine months ended September 30, 2025, there was an increase in fair value of $782,404 related to the change in fair value of the Company’s shares in AlloTera Therapeutics and the related contingent liability, a loss of $182,146 on the sale of put shares through the Company’s Standby Equity Purchase Agreement. In the nine months ended September 30, 2026, there was a $1.8 million nonoperating loss, primarily consisting of a $1.8 million decrease in the fair value of a warrant liability, which was reclassified to equity in this period.

Net loss: Net loss for the three months ended September 30, 2025 and 2026 was $4.6 million and $3.2 million, respectively. Net loss for the nine months ended September 30, 2025 and 2026, was $8.7 million and $5.0 million, respectively.

Financial Guidance

As of September 30, 2026, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support. We considered future elements of our financing plan, but we cannot be assured that we will continue to have success with remaining elements of our plan.

On June 26, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was in compliance with Listing Rule 5550(b)(1) (the “Equity Rule”). On October 2, 2026, the Company received formal notice from Nasdaq that the Company maintained compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule,” along with all of the applicable continued listing requirements until September 22, 2026, as required by the Panel decision dated May 29, 2026, as amended.

About HCW Biologics

HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. HCW Biologics is the leader in creation of multi-valent immunotherapeutics with a unique protein-based scaffold, without the antibody Fc domain. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/

Forward Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including timing and efficacy in human clinical trial data for HCW9302, including timing of completion of Phase 1 in the first quarter of 2027, ability of HCW11-018b to treat solid tumors, ability to obtain U.S. Food and Drug Administration clearance to advance Phase 2 clinical trials for HCW9302, success in obtaining FDA clearance to initiate clinical trials for HCW11-018b, and effectiveness of commercial-ready reagents for production of immunotherapeutics; and the Company’s ability to license or sell reagents. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 31, 2026, the Form 10-Q filed with the SEC on November 16, 2026, and in other filings filed from time to time with the SEC. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact:

Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com

HCW Biologics Inc.
Condensed Statements of Operations
(Unaudited)
       
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
  2025  2026  2025  2026 
Revenues:                
Revenues $15,606  $55,463  $27,222  $6,734,032 
Cost of revenues  (12,485)  (27,345)  (21,777)  (267,871)
Gross Profit  3,121   28,118   5,445   6,466,161 
                 
Operating expenses:                
Research and development  1,404,247   1,242,577   4,109,782   3,703,877 
General and administrative  1,884,994   1,366,386   6,187,296   5,070,038 
Legal expenses (recoveries), net  6,006   9,058   (1,590,945)  14,583 
Indirect tax expense  -   -   -   198,146 
Total operating expenses  3,295,247   2,618,021   8,706,133   8,986,644 
Operating loss  (3,292,126)  (2,589,903)  (8,700,688)  (2,520,483)
Interest expense  (127,070)  (141,797)  (632,923)  (351,612)
Change in fair value of contingent liability, net  1,055,825   -   (692,531)  - 
Change in fair value of investment, net  (2,022,109)  -   1,474,935   - 
Change in fair value of warrant liability  -   -   -   (1,775,992)
Loss on sale of put shares  (182,146)  -   (182,146)  - 
Loss on return of equipment  -   (494,683)  -   (494,683)
Gain on extinguishment of liability  -   -   -   483,383 
Other income, net  13,290   3,554   54,412   19,992 
Net loss before income taxes  (4,554,336)  (3,222,829)  (8,678,941)  (4,639,395)
Income tax expense  -   -   -   (330,186)
Net loss $(4,554,336) $(3,222,829) $(8,678,941) $(4,969,581)
Equity dividend to investor  -   (2,718,837)  (10,153,799)  (14,361,951)
Net loss attributable to Common Stockholders $(4,554,336) $(5,941,666) $(18,832,740) $(19,331,532)
Net loss per share, basic and diluted $(12.09) $(2.83) $(68.02) $(13.35)
Weighted average shares outstanding, basic and diluted  376,678   2,101,872   276,889   1,448,485 
                 


HCW Biologics Inc.
Condensed Balance Sheets
       
  December 31,  September 30, 
  2025  2026 
     Unaudited 
ASSETS        
Current assets:        
Cash and cash equivalents $1,952,464  $955,458 
Accounts receivable, net  32,175   - 
Prepaid expenses  222,156   239,998 
Other current assets  77,564   85,202 
Total current assets  2,284,359   1,280,658 
Investments  1,326,329   4,854,028 
Property, plant and equipment, net  20,880,849   18,963,834 
Other assets  28,476   28,476 
Total assets $24,520,013  $25,126,996 
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Liabilities        
Current liabilities:        
Accounts payable $13,143,394  $9,435,785 
Accrued liabilities and other current liabilities  1,110,104   1,046,440 
Short-term debt, net  6,809,215   6,831,899 
Deferred revenue  —   297,101 
Total current liabilities  21,062,713   17,611,225 
Contingent liability - related party  692,531   692,531 
Total liabilities  21,755,244   18,303,756 
Commitments and contingencies (Note 12)        
Stockholders’ equity:        
Common stock:        
Common, $0.0001 par value; 250,000,000 shares authorized and 546,635 shares issued at December 31, 2025; 250,000,000 shares authorized and 2,236,324 shares issued at September 30, 2026  55   223 
Additional paid-in capital  111,280,560   120,308,443 
Accumulated deficit  (108,515,846)  (113,485,426)
Total stockholders’ equity  2,764,769   6,823,240 
Total liabilities and stockholders’ equity $24,520,013  $25,126,996 


This press release was published by a CLEAR® Verified individual.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does HCW Biologics expect HCW9302 Phase 1 results?

HCW Biologics expects the Phase 1 readout and recommended Phase 2 dose in the first quarter of 2027, with continued patient enrollment. The trial evaluates HCW9302 in alopecia areata. The company intends to present full results at the Treg-Directed Therapies Summit in March 2027.

How much funding did HCW Biologics secure in November 2026?

HCW Biologics secured up to $10.0 million through debt financing on November 4, 2026. It received $3.0 million, less transaction costs, at closing, with access to another $7.0 million subject to conditions. The company believes this financing supports completion of HCW9302 Phase 1 and selection of the recommended Phase 2 dose.

Keep reading